Financings in Brief: Calypte Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Calypte Biomedical: Private placement of common stock through placement agent Pacific Growth Equities raises $10 mil. The proceeds will allow the Alameda, California firm to complete scale-up of manufacturing for its urine-based test for HIV-1. In September, Cambridge Biotech received an approvable letter for the urine-based Western Blot confirmatory test for use in conjunction with the Calypte test ("The Gray Sheet" Sept. 22, In Brief). Funds from the offering will also "allow us to initiate the development of additional urine-based diagnostic tests including the Calypte HIV-1 urine test for home collection, and to undertake the clinical trials required for this application," President and CEO Jack Davis states...
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.